-
Je něco špatně v tomto záznamu ?
Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma
AM. Rose, LC. Spender, C. Stephen, A. Mitchell, W. Rickaby, S. Bray, AT. Evans, J. Dayal, KJ. Purdie, CA. Harwood, CM. Proby, IM. Leigh, PJ. Coates, GJ. Inman,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
- Publikační typ
- časopisecké články MeSH
The incidence of cutaneous squamous cell carcinoma (cSCC) is rising. Whilst the majority are cured surgically, aggressive metastatic cSCC carry a poor prognosis. Inactivating mutations in transforming growth factor beta (TGF-β) receptors have been identified amongst genetic drivers of sporadic tumours and murine models of cSCC, suggesting a tumour suppressor function for TGF-β in normal skin. However, paradoxically, TGF-β acts as a tumour promoter in some murine model systems. Few studies have analysed the role of TGF-β/activin signalling in human normal skin, hyper-proliferative skin disorders and cSCC. Antibodies recognising phospho-SMAD proteins which are activated during canonical TGF-β/activin signalling were validated for use in immunohistochemistry. A tissue microarray comprising FFPE lesional and perilesional tissue from human primary invasive cSCC (n=238), cSCCin-situ(n=2) and keratocanthoma (n=9) were analysed in comparison with tissues from normal human scalp (n=10). Phosphorylated SMAD2 and SMAD3 were detected in normal interfollicular epidermal keratinocytes and were also highly localised to inner root sheath, matrix cells and Keratin 15 positive cells. Lesional cSCC tissue had significantly reduced activated SMAD2/3 compared to perilesional tissue, consistent with a tumour suppressor role for SMAD2/3 activators in cSCC. Increased cSCC tumour thickness inversely correlated with the presence of phospho-SMADs in tumour tissue suggesting that a reduction in canonical TGF-β/activin signalling may be associated with disease progression.
Department of Pathology Ninewells Hospital and Medical School NHS Tayside Dundee Scotland DD1 9SY UK
Dermatopathology Laboratory St John's Institute of Dermatology St Thomas' Hospital London SE1 7EH UK
Tayside Tissue Bank Ninewells Hospital and Medical School NHS Tayside Dundee Scotland DD1 9SY UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18009903
- 003
- CZ-PrNML
- 005
- 20180405103347.0
- 007
- ta
- 008
- 180404s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.18632/oncotarget.24545 $2 doi
- 035 __
- $a (PubMed)29581863
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rose, Aidan M $u Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK. Department of Plastic and Reconstructive Surgery, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, DD1 9SY, UK.
- 245 10
- $a Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma / $c AM. Rose, LC. Spender, C. Stephen, A. Mitchell, W. Rickaby, S. Bray, AT. Evans, J. Dayal, KJ. Purdie, CA. Harwood, CM. Proby, IM. Leigh, PJ. Coates, GJ. Inman,
- 520 9_
- $a The incidence of cutaneous squamous cell carcinoma (cSCC) is rising. Whilst the majority are cured surgically, aggressive metastatic cSCC carry a poor prognosis. Inactivating mutations in transforming growth factor beta (TGF-β) receptors have been identified amongst genetic drivers of sporadic tumours and murine models of cSCC, suggesting a tumour suppressor function for TGF-β in normal skin. However, paradoxically, TGF-β acts as a tumour promoter in some murine model systems. Few studies have analysed the role of TGF-β/activin signalling in human normal skin, hyper-proliferative skin disorders and cSCC. Antibodies recognising phospho-SMAD proteins which are activated during canonical TGF-β/activin signalling were validated for use in immunohistochemistry. A tissue microarray comprising FFPE lesional and perilesional tissue from human primary invasive cSCC (n=238), cSCCin-situ(n=2) and keratocanthoma (n=9) were analysed in comparison with tissues from normal human scalp (n=10). Phosphorylated SMAD2 and SMAD3 were detected in normal interfollicular epidermal keratinocytes and were also highly localised to inner root sheath, matrix cells and Keratin 15 positive cells. Lesional cSCC tissue had significantly reduced activated SMAD2/3 compared to perilesional tissue, consistent with a tumour suppressor role for SMAD2/3 activators in cSCC. Increased cSCC tumour thickness inversely correlated with the presence of phospho-SMADs in tumour tissue suggesting that a reduction in canonical TGF-β/activin signalling may be associated with disease progression.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Spender, Lindsay C $u Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK.
- 700 1_
- $a Stephen, Christopher $u Department of Plastic and Reconstructive Surgery, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, DD1 9SY, UK.
- 700 1_
- $a Mitchell, Alastair $u Department of Dermatology, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, DD1 9SY, UK.
- 700 1_
- $a Rickaby, William $u Dermatopathology Laboratory, St. John's Institute of Dermatology, St.Thomas' Hospital, London, SE1 7EH, UK.
- 700 1_
- $a Bray, Susan $u Tayside Tissue Bank, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, DD1 9SY, UK.
- 700 1_
- $a Evans, Alan T $u Department of Pathology, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, DD1 9SY, UK.
- 700 1_
- $a Dayal, Jasbani $u Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK.
- 700 1_
- $a Purdie, Karin J $u Centre for Cell Biology and Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, UK.
- 700 1_
- $a Harwood, Catherine A $u Centre for Cell Biology and Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, UK.
- 700 1_
- $a Proby, Charlotte M $u Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK.
- 700 1_
- $a Leigh, Irene M $u Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK. Centre for Cell Biology and Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, UK.
- 700 1_
- $a Coates, Philip J $u Tayside Tissue Bank, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, DD1 9SY, UK. Regional Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, 656 53, Czech Republic.
- 700 1_
- $a Inman, Gareth J $u Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK.
- 773 0_
- $w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 9, č. 18 (2018), s. 14552-14566
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29581863 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180405103428 $b ABA008
- 999 __
- $a ind $b bmc $g 1287388 $s 1006715
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 9 $c 18 $d 14552-14566 $e 20180222 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
- LZP __
- $a Pubmed-20180404
